Original Literature | Model OverView |
---|---|
Publication
Title
An arms race: innate antiviral responses and counteracting viral strategies.
Affiliation
Viral Immune Evasion Group, School of Biochemistry and Immunology, TrinityCollege Dublin, Dublin 2, Ireland. schrodem@tcd.ie
Abstract
Viral recognition is mediated by different classes of PRRs (pattern-recognitionreceptors) among which the TLRs (Toll-like receptors) and the RLHs [RIG(retinoic-acid-inducible)-like helicases] play major roles. The detection ofPAMPs (pathogen-associated molecular patterns) by these PRRs leads to theinitiation of signalling pathways that ultimately result in the activation oftranscription factors such as NF-kappaB (nuclear factor kappaB) and IRF-3 [IFN(interferon) regulatory factor-3] and IRF-7 and the induction ofpro-inflammatory cytokines and type I IFNs. Viruses have evolved a fine-tunedmechanism to evade detection by the immune system or to interfere with theresulting signalling pathways. Here, we discuss viral evasion proteins thatspecifically interfere with TLR and/or RLH signalling.
PMID
18031256
|
Entity
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m25
10
infinite
0
TRANSPATH | MO000000058 |
--
IRF-3
--
MO000007694
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m977
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
PKR(DAI)[
--
MO000008179
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1055
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000008179 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
IKK-i
--
MO000016608
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1599
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016608 |
--
TBK1
--
MO000019331
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3902
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019331 |
--
dsRNA
--
MO000022224
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m119368
10
infinite
0
TRANSPATH | MO000022224 |
--
TRIF
--
MO000041125
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m18998
10
infinite
0
TRANSPATH | MO000041125 |
--
dsRNA:TLR3
--
MO000041446
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19314
10
infinite
0
TRANSPATH | MO000041446 |
--
RIG-1
--
MO000066987
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m41844
10
infinite
0
TRANSPATH | MO000066987 |
--
IPS-1
--
MO000094908
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m68199
10
infinite
0
TRANSPATH | MO000094908 |
--
IFIH1(mda-5)
--
MO000103999
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m76904
10
infinite
0
TRANSPATH | MO000103999 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
--
e12
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m12
0
infinite
0
--
--
e13
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m13
0
infinite
0
--
--
e14
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m14
0
infinite
0
--
csml-variable:Double
m15
0
infinite
0
--
ssRNA: TLR8
--
e16
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m16
0
infinite
0
--
CpGDNA: TLR9
--
e17
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m17
0
infinite
0
--
dsRNA: RIG-1
--
e18
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m18
0
infinite
0
--
dsRNA: mda-5
--
e19
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
ssRNA: TLR7: MyD88
--
e20
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m20
0
infinite
0
--
ssRNA: TLR8: MyD88
--
e21
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m21
0
infinite
0
--
CpGDNA: TLR9: MyD88
--
e22
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m22
0
infinite
0
--
IRF-3 {activated}
--
e23
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m23
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
dsRNA:TLR3: TRIF
--
e24
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m24
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma
--
e25
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m26
10
infinite
0
TRANSPATH | MO000016661 |
--
TLR ligand
--
e26
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m27
0
infinite
0
--
TLR ligand: TLR
--
e27
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m28
0
infinite
0
--
TLR ligand: TLR: MyD88
--
e28
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
TRAF6 {activated}
--
e29
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m30
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma {activated}
--
e31
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m32
10
infinite
0
TRANSPATH | MO000016661 |
--
IkappaB {activated}
--
e32
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m33
10
infinite
0
TRANSPATH | MO000000215 |
--
NF-kappaB {activated}
--
e33
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m34
10
infinite
0
TRANSPATH | MO000000058 |
--
TLR4 ligand
--
e34
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m35
0
infinite
0
--
TLR4 ligand: TLR4
--
e35
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m36
0
infinite
0
--
TLR4 ligand: TLR4: TRIF
--
e37
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m38
0
infinite
0
--
IKK-i {activated}
--
e39
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m40
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016608 |
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
TBK1 {activated}
--
e40
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m41
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019331 |
--
IRF
--
e41
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m42
0
infinite
0
--
IRF {activated}
--
e42
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m43
0
infinite
0
--
csml-variable:Double
m44
0
infinite
0
--
csml-variable:Double
m45
0
infinite
0
--
dsDNA: DAI: TBK1
--
e45
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
v protein
--
e46
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m47
0
infinite
0
--
NS1
--
e47
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m48
0
infinite
0
--
NS1: RIG-1
--
e48
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m49
0
infinite
0
--
v protein: mda-5
--
e49
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
CpGDNA
--
e5
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
ssRNA
--
e6
cso30:c:Rna
cso30:i:CC_Extracellular
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
VP35
--
e64
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m65
0
infinite
0
--
dsRNA: VP35
--
e65
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m66
0
infinite
0
--
NS3/4a
--
e66
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m67
0
infinite
0
--
protein remnants
--
e67
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m68
10
infinite
0
TRANSPATH | MO000019479 |
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
A52
--
e70
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m71
0
infinite
0
--
A52: TRAF6
--
e71
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m72
0
infinite
0
--
A52: IRAK-2
--
e72
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m73
0
infinite
0
--
csml-variable:Double
m76
0
infinite
0
--
csml-variable:Double
m77
0
infinite
0
--
csml-variable:Double
m78
0
infinite
0
--
csml-variable:Double
m79
0
infinite
0
--
csml-variable:Double
m80
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m119368*m3965*0.1
nodelay
--
0
PMID: 18031256 TLR3 detects viral dsRNA (double-stranded RNA), e.g. purified genomic RNA from reovirus or the synthetic dsRNA analogue poly(I:C).
p10
p10
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m18998*m19314*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m27*m3962*0.1
nodelay
--
0
PMID: 18031256 TLR signalling to NF-kappaB proceeds mainly via MyD88, the IRAKs [IL-1 (interleukin-1) receptor-associated kinases] and TRAF-6 (tumour-necrosis-factor-receptor-associated factor-6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m28*m1572*0.1
nodelay
--
0
PMID: 18031256 TLR signalling to NF-kappaB proceeds mainly via MyD88, the IRAKs [IL-1 (interleukin-1) receptor-associated kinases] and TRAF-6 (tumour-necrosis-factor-receptor-associated factor-6).
p13
p13
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c40 : 1
stoichiometry:c41 : 1
m29*m184*0.1
nodelay
--
0
PMID: 18031256 TLR signalling to NF-kappaB proceeds mainly via MyD88, the IRAKs [IL-1 (interleukin-1) receptor-associated kinases] and TRAF-6 (tumour-necrosis-factor-receptor-associated factor-6).
p14
p14
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c42 : 1
stoichiometry:c39 : 1
m183*m31*0.1
nodelay
--
0
PMID: 18031256 TLR signalling to NF-kappaB proceeds mainly via MyD88, the IRAKs [IL-1 (interleukin-1) receptor-associated kinases] and TRAF-6 (tumour-necrosis-factor-receptor-associated factor-6).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c45 : 1
stoichiometry:c44 : 1
m26*m30*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p16
p16
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c48 : 1
stoichiometry:c47 : 1
m186*m32*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p17
p17
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c51 : 1
stoichiometry:c160 : 1
stoichiometry:c50 : 1
m25*m33*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7. PMID: 18031256 Through its interaction with IRAK2, it inhibits TLR-induced NF-kappaB activation and interferes with the induction of pro-inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c54 : 1
m35*m3961*0.1
nodelay
--
0
p19
p19
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c93 : 1
stoichiometry:c88 : 1
m3902*m20*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c8 : 1
m6*m19940*0.1
nodelay
--
0
PMID: 18031256 ssRNA (single-stranded RNA) (such as from influenza virus and HIV-1) is the ligand for TLR7/8.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c60 : 1
stoichiometry:c59 : 1
m36*m18998*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
p21
p21
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c61 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
stoichiometry:c62 : 1
m977*m40*m41*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p22
p22
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c63 : 1
stoichiometry:c71 : 1
stoichiometry:c72 : 1
stoichiometry:c64 : 1
m980*m41*m40*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p23
p23
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c75 : 1
stoichiometry:c66 : 1
m1599*m24*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p24
p24
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c67 : 1
stoichiometry:c76 : 1
stoichiometry:c68 : 1
m3902*m24*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p25
p25
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c78 : 1
stoichiometry:c84 : 1
m22*m1599*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9. PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p26
p26
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c85 : 1
stoichiometry:c77 : 1
m1599*m21*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9. PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p27
p27
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c86 : 1
stoichiometry:c56 : 1
m1599*m20*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9. PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p28
p28
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c80 : 1
stoichiometry:c79 : 1
m1599*m38*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p29
p29
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c74 : 1
stoichiometry:c83 : 1
stoichiometry:c82 : 1
m3902*m38*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c6 : 1
stoichiometry:c7 : 1
stoichiometry:c9 : 1
m6*m19823*0.1
nodelay
--
0
PMID: 18031256 ssRNA (single-stranded RNA) (such as from influenza virus and HIV-1) is the ligand for TLR7/8.
p30
p30
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c94 : 1
stoichiometry:c90 : 1
m3902*m21*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
p31
p31
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c95 : 1
stoichiometry:c92 : 1
m3902*m22*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c96 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
stoichiometry:c97 : 1
m42*m40*m41*0.1
nodelay
--
0
PMID: 18031256 Even though their upstream signalling pathways are distinct, it seems that the signalling pathways elicited by the different classes of PRRs converge at the level of the IKK [IkappaB (inhibitory kappaB) kinase] complex (containing IKK-alpha, -beta and -gamma) for activation of NF-kappaB and the related kinases IKK-epsilon and TBK1 (TANK-binding kinase-1) for activation of IRF-3 and IRF-7. PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c16 : 1
stoichiometry:c102 : 1
m44*m1055*0.1
nodelay
--
0
PMID: 18031256 It was demonstrated that DAI can respond to dsDNA (of mammalian, viral or bacterial origin) with the induction of an IFN response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
stoichiometry:c105 : 1
m3902*m45*0.1
nodelay
--
0
PMID: 18031256, 17618271 The newly discovered DNA receptor DAI also appears to engage TBK1 for activation of IRF-3.
p35
p35
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c108 : 1
stoichiometry:c107 : 1
m977*m46*0.1
nodelay
--
0
PMID: 18031256, 17618271 The newly discovered DNA receptor DAI also appears to engage TBK1 for activation of IRF-3.
p36
p36
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c169 : 1
stoichiometry:c113 : 1
m47*m76904*0.1
nodelay
--
0
PMID: 18031256 Recently, a couple of viral proteins have been described to prevent RNA detection through RIG-I and mda-5, e.g. the paramyxovirus V proteins, which bind to mda-5, and influenza virus NS1, which binds to RIG-I.
p37
p37
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c109 : 1
stoichiometry:c110 : 1
stoichiometry:c111 : 1
m48*m41844*0.1
nodelay
--
0
PMID: 18031256 Recently, a couple of viral proteins have been described to prevent RNA detection through RIG-I and mda-5, e.g. the paramyxovirus V proteins, which bind to mda-5, and influenza virus NS1, which binds to RIG-I.
p38
p38
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c118 : 1
stoichiometry:c121 : 1
stoichiometry:c101 : 1
m119368*m1055*0.1
nodelay
--
0
PMID: 18031256 Other proteins such as Ebola virus VP35 bind to the dsRNA and thereby prevent detection by RIG-I and also PKR.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c122 : 1
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m65*m119368*0.1
nodelay
--
0
PMID: 18031256 Other proteins such as Ebola virus VP35 bind to the dsRNA and thereby prevent detection by RIG-I and also PKR.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m5*m19828*0.1
nodelay
--
0
PMID: 18031256 Unmethylated viral CpG DNA [such as from HSV-2 (herpes simplex virus-2)] can stimulate TLR9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c126 : 1
stoichiometry:c129 : 1
m67*m18998*0.1
nodelay
--
0
PMID: 18031256, 17307033 Hepatitis C virus expresses the protease NS3/4a, which cleaves TRIF and the RLH (RIG-like helicase) adaptor IPS-1 and thereby specifically targets and evades TLR3- and TLR4- as well as RLH-signalling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c130 : 1
stoichiometry:c128 : 1
stoichiometry:c127 : 1
m67*m68199*0.1
nodelay
--
0
PMID: 18031256, 17307033 Hepatitis C virus expresses the protease NS3/4a, which cleaves TRIF and the RLH (RIG-like helicase) adaptor IPS-1 and thereby specifically targets and evades TLR3- and TLR4- as well as RLH-signalling. PMID: 18031256 Furthermore, from the finding that cleavage of IPS-1 by NS3/4a releases it from the mitochondrial membrane, we learned that the mitochondrial attachment of IPS-1 is functionally important.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c132 : 1
stoichiometry:c136 : 1
m183*m71*0.1
nodelay
--
0
PMID: 18031256 A52 interacts with the downstream TLR signalling molecules TRAF-6 and IRAK2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c135 : 1
stoichiometry:c133 : 1
m1569*m71*0.1
nodelay
--
0
PMID: 18031256 A52 interacts with the downstream TLR signalling molecules TRAF-6 and IRAK2.
p44
p44
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c139 : 1
stoichiometry:c138 : 1
m74*m72*0.1
nodelay
--
0
PMID: 18031256, 12566418, 15998638 On the other hand, its interaction with TRAF-6 mediates p38 MAPK (mitogen-activated protein kinase) activation and induction of the anti-inflammatory cytokine IL-10.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c140 : 1
stoichiometry:c141 : 1
m75*0.1
nodelay
--
0
PMID: 18031256, 12566418, 15998638 On the other hand, its interaction with TRAF-6 mediates p38 MAPK (mitogen-activated protein kinase) activation and induction of the anti-inflammatory cytokine IL-10.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c151 : 1
m71*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c152 : 1
m76*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c146 : 1
stoichiometry:c153 : 1
m77*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c143 : 1
stoichiometry:c154 : 1
m71*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
p5
p5
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c115 : 1
stoichiometry:c120 : 1
stoichiometry:c17 : 1
m119368*m41844*0.1
nodelay
--
0
PMID: 18031256, 15208624 However, when two related DEXD/H-box RNA helicases RIG-I [RIG (retinoic-acid-inducible) protein I] and mda-5 (melanoma differentiation-associated gene-5) were described as novel cytoplasmic PRRs for viral dsRNA. PMID: 18031256 Recently, a couple of viral proteins have been described to prevent RNA detection through RIG-I and mda-5, e.g. the paramyxovirus V proteins, which bind to mda-5, and influenza virus NS1, which binds to RIG-I. PMID: 18031256 Other proteins such as Ebola virus VP35 bind to the dsRNA and thereby prevent detection by RIG-I and also PKR.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c155 : 1
m76*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c156 : 1
m77*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c150 : 1
stoichiometry:c157 : 1
m71*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c149 : 1
stoichiometry:c158 : 1
m76*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c159 : 1
m77*0.1
nodelay
--
0
PMID: 18031256, 15215253, 15016878, 15016878 Apart from A46 and A52, VACV encodes a whole range of immunomodulatory proteins, including several NF-kappaB inhibitors, such as N1 [9], K1 [10] and M2[11].
p56
p56
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c164 : 1
stoichiometry:c163 : 1
stoichiometry:c168 : 1
stoichiometry:c165 : 1
m977*m41844*m68199*0.1
nodelay
--
0
PMID: 18031256 The signalling pathway emanating from RIG-I is still less well defined, but it involves amitochondrial adaptor molecule called IPS-1 (IFNbeta promoter stimulator) [also called MAVS (mitochondrial antiviral signalling), Cardif [CARD (caspase recruitment domain) adaptor inducing IFN¦Â] orVISA (virusinduced signalling activator)] for activation of both NF-kappaB and IRF-3.
p57
p57
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c166 : 1
stoichiometry:c161 : 1
stoichiometry:c162 : 1
stoichiometry:c167 : 1
m25*m41844*m68199*0.1
nodelay
--
0
PMID: 18031256 The signalling pathway emanating from RIG-I is still less well defined, but it involves amitochondrial adaptor molecule called IPS-1 (IFNbeta promoter stimulator) [also called MAVS (mitochondrial antiviral signalling), Cardif [CARD (caspase recruitment domain) adaptor inducing IFN¦Â] orVISA (virusinduced signalling activator)] for activation of both NF-kappaB and IRF-3.
p6
p6
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c116 : 1
stoichiometry:c170 : 1
stoichiometry:c18 : 1
m119368*m76904*0.1
nodelay
--
0
PMID: 18031256, 15208624 However, when two related DEXD/H-box RNA helicases RIG-I [RIG (retinoic-acid-inducible) protein I] and mda-5 (melanoma differentiation-associated gene-5) were described as novel cytoplasmic PRRs for viral dsRNA. PMID: 18031256 Recently, a couple of viral proteins have been described to prevent RNA detection through RIG-I and mda-5, e.g. the paramyxovirus V proteins, which bind to mda-5, and influenza virus NS1, which binds to RIG-I.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
m15*m1572*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c24 : 1
stoichiometry:c23 : 1
m16*m1572*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c27 : 1
stoichiometry:c26 : 1
m17*m1572*0.1
nodelay
--
0
PMID: 18031256, 16006187 TLR3- and TLR4-induced IRF activation is mediated by TRIF, whereas MyD88 (myeloid differentiation factor 88) is sufficient for IRF activation induced by TLR7, 8 and 9.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--